KONEXElectronic Components448780

Micro-NX

₩689▼ 0.14%2026-11-18 close
Market Cap
₩1.8B
Turnover
₩3,290
Volume
5 shares
Shares out.
2.7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Dental Motor Know-how, Profit Recovery Still Pending

Micro-NX has a specialized position in dental precision motors, but sales, operating profit and net income all weakened in 2025 and the company swung to a net loss, making profitability recovery the central issue.

  1. 1

    Sales in 2025 fell 5% year on year to KRW 7.82 billion, with operating profit of KRW 367 million and a net loss of KRW 143 million (separate basis, as disclosed).

  2. 2

    Completion of FDA certification for three ISE-170 series models in July 2025 and rising demand for electrified dental equipment are cited as growth drivers.

  3. 3

    Supply contracts with domestic implant makers and export contracts in Central Asia, Russia and Azerbaijan form the revenue base, yet sales have declined for three consecutive years.

  4. 4

    The current ratio fell from 215.5% in 2023 to 89.1% in 2025, and net cash outflow from investing activities widened to KRW 3.69 billion in 2025 from KRW 1.62 billion in 2024.

  5. 5

    The share price moved from KRW 1,598 on March 31, 2026 to KRW 677 on October 22, 2026, and the market capitalization is about KRW 1.9 billion.

02

Business structure

Micro-NX is a dental medical device maker founded in July 2001 and based in Daegu. Although the market classification is Electronics & Components, the actual business centers on dental equipment. Its core products are implant surgical units, electric motor systems and handpieces used in dental laboratories and clinics.

The company describes its capability as manufacturing small medical micromotors on a Swiss-type design, which it applies to localized development, design, manufacturing and export of dental devices.

Its customer base is anchored in supply contracts with major domestic implant makers, which form the foundation of domestic revenue.

Overseas, following a Central Asian dental equipment exhibition in October 2022, the company signed annual supply contracts for more than 200 engine and handpiece units with firms in Kazakhstan, Uzbekistan and Kyrgyzstan.

In the same year it signed an OEM contract for more than 300 surgical implant engines per year with firms in Russia and Azerbaijan. On certification, a Micro-NX product received US FDA approval in November 2023 and three ISE-170 series models completed FDA certification in July 2025.

The company says it holds more than 30 domestic and overseas intellectual property rights. A July 2026 report cited by the press pointed to growing electrification and precision in dental medical devices.

Competitive positioning in dental motors and handpieces depends on reliance on implant makers and on securing overseas certifications.

03

Recent trends

Recent results show shrinking sales and weaker profitability at the same time. On a separate basis, 2025 sales were KRW 7,819 million, down from KRW 8,247 million in 2024, with operating profit of KRW 367 million and a net loss of KRW 143 million.

On a consolidated basis, 2025 sales were KRW 7,937 million and operating profit was KRW 351 million, with the net loss at the same KRW 143 million. Sales have declined for three straight years, from KRW 8.35 billion in 2023 to KRW 8.25 billion in 2024 and KRW 7.82 billion in 2025.

Operating profit fell from KRW 590.6 million in 2023 to KRW 527.8 million in 2024 and KRW 367.6 million in 2025, giving a 4.7% operating margin in 2025. Net income of KRW 166.4 million in 2023 and KRW 414.4 million in 2024 turned into a loss in 2025.

At year-end 2025, total assets were KRW 25.05 billion, total liabilities KRW 13.58 billion and equity KRW 11.46 billion, a debt ratio of 118.50%. The current ratio dropped from 215.5% in 2023 to 89.1% in 2025.

Net cash outflow from investing activities widened to KRW 3.69 billion in 2025 from KRW 1.62 billion in 2024, while operating cash flow from ordinary activities was an inflow of KRW 391 million.

The share price fell from KRW 1,598 on March 31, 2026 to KRW 677 on October 22, 2026, a year-to-date decline of 67.61% as of that date.

04

Outlook

The outlook balances expansion drivers against uncertainty over earnings recovery. An analysis reported in July 2026 pointed to growing demand for small precision motors as dental devices become more electrified and precise.

With three ISE-170 models certified by the FDA in July 2025, the pace of US sales is cited as a key factor for medium-term growth. At the 2022 listing, the CEO said the company would widen new domestic and overseas customer relationships and pursue a future KOSDAQ listing.

However, with sales down for three consecutive years and operating profit declining, whether new customer wins translate into a sales rebound remains the central question.

On the financial side, the larger investing cash outflow in 2025 and the lower current ratio of 89.1% make working capital funding and capex direction key items to track alongside earnings.

Medium-term scenarios diverge: export growth and rising electrified-device sales could restore profitability, or reliance on implant makers could persist and leave sales flat. The company's next periodic disclosures and the revenue contribution of its FDA-certified products will indicate which path is developing.

05

Bull factors

Certifications and technology assets

Following FDA approval for an Endoit product in November 2023, three ISE-170 series models completed FDA certification in July 2025.

Built on a track record of nearly 26 years since its 2001 founding, the company has accumulated small medical micromotor technology and says it holds more than 30 domestic and overseas intellectual property rights.

If electrification in dental equipment continues, these certifications and technology assets could serve as a basis for overseas market entry.

Overseas supply contract base

Following a Central Asian dental equipment exhibition in October 2022, the company signed annual supply contracts for more than 200 engine and handpiece units with firms in Kazakhstan, Uzbekistan and Kyrgyzstan.

Export contracts that go beyond a domestic implant-maker base are cited as a strength in customer diversification.

Cash generation above operating profit

Cash operating profit in 2025 was KRW 888 million, above operating profit of KRW 368 million. Operating cash flow from ordinary activities also recorded an inflow of KRW 391 million in the same year. Maintaining cash generation despite the shift to a net loss can be seen as a factor easing near-term financial strain.

Cash operating profit is a derived metric, so its components, including depreciation, need to be read alongside it.

06

Bear factors

Sales and earnings both shrinking

Sales declined for three consecutive years, from KRW 8.35 billion in 2023 to KRW 8.25 billion in 2024 and KRW 7.82 billion in 2025. Operating profit fell from KRW 590.6 million in 2023 to KRW 367.6 million in 2025, and 2025 turned into a net loss of KRW 143 million. Compared with KRW 8.73 billion in 2022, the reduction in top-line size is the clearest weakness.

Short-term liquidity and investment burden

The current ratio declined from 215.5% in 2023 to 89.1% in 2025. The debt ratio stood at 118.50% at year-end 2025, and the borrowing dependence ratio was 47.57%. Net cash outflow from investing activities rose to KRW 3.69 billion in 2025 from KRW 1.62 billion in 2024. Higher investment spending while sales were contracting constrains financial flexibility.

Share price weakness and KONEX liquidity

The share price fell from KRW 1,598 on March 31, 2026 to KRW 677 on October 22, 2026, a 67.61% year-to-date decline as of that date. The market capitalization of about KRW 1.9 billion places the company among small caps.

KONEX is a market focused on early-stage small and venture companies, where trading volume tends to be thin and price swings can be large. Such trading conditions can cause the share price to diverge from reported results.

07

Risk factors

Macro

Interest rate levels and KRW-USD movements can affect export pricing, borrowing costs and imported component costs. As overseas sales grow, exposure to exchange-rate moves increases. A slowdown in dental treatment and implant procedure demand could also weigh on supply volumes.

Overseas sales depend on country-specific device approvals, including the US FDA and China's NMPA. Delayed renewals or changed regulatory requirements could halt sales in the affected market.

The company renewed its NMPA certification in March 2024, so the management of certifications is directly linked to earnings stability.

Domestic revenue relies on supply contracts with implant manufacturers. A reduction in orders from a major customer could increase revenue volatility. With the current ratio at a low level, continued investment spending could require additional funding, adding financial pressure.

08

Overall view

Micro-NX is a KONEX-listed company with nearly 26 years of history, built on dental precision motors and implant surgical unit technology. Based on 2025 disclosures, sales declined for a third consecutive year and operating profit shrank, turning the bottom line into a net loss.

Strengths include FDA-certified products, export supply contracts, and cash operating profit in 2025 that exceeded operating profit. Weaknesses include a contraction in sales, a low current ratio of 89.1%, a wider investing cash outflow, and a sharp share price decline in 2026.

Because the market classification (Electronics & Components) differs from the actual business (dental medical devices), interpretation of sector-level figures is broad.

Demand growth for electrified dental equipment is cited as an opportunity, but whether it has produced a sales rebound is not yet visible in the disclosed figures. This report is provided for information only, and interpretation may change with subsequent disclosures and business reports.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. m.news.nate.com
  2. jobkorea.co.kr
  3. jobkorea.co.kr
  4. m.saramin.co.kr
  5. saramin.co.kr
  6. thevc.kr
  7. sedaily.com
  8. imaeil.com
  9. dentalarirang.com
  10. in.marketscreener.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis